Beta
Back to PFE.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
net-income-chart

PFE Net Income

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

The latest data point for Pfizer's (PFE) net income in Q4'25 shows a loss of $1.65B USD, marking a downturn from the positive $3.54B USD recorded in Q3'25 and contributing to a volatile fiscal year-end performance. Over the period from Q1'23 to Q4'25, net income exhibited significant fluctuations, starting with a strong $5.54B USD in Q1'23 before declining sharply to losses of $2.38B USD in Q3'23 and $3.37B USD in Q4'23, reflecting an overall downward trend in 2023 with year-over-year (YoY) declines peaking at -167%. Recovery emerged in 2024, with profits rebounding to $4.47B USD in Q3'24 amid YoY growth of 287%, though Q4'24 moderated to $0.41B USD; 2025 showed mixed results, including a robust 70% YoY surge to $2.91B USD in Q2'25, but ending with the Q4 loss and a stark -502% YoY drop, underscoring persistent volatility likely tied to pharmaceutical market dynamics. The YoY line chart highlights these swings, with negative percentages dominating early periods before sporadic positive spikes in later quarters.